Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration (USFDA) to market Letermovir tablets, 240 mg and 480 mg, (USRLD: Prevymis® tablets). Letermovir tablets are used to prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received a bone marrow transplant or kidney transplant. The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.